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ABSTRACT
This study compared MIC distributions of
amoxycillin–clavulanate obtained with NCCLS
and French (Comite´ de l’Antibiogramme de la
Socie´te´ Franc¸aise de Microbiologie; CA-SFM)
methodologies for Escherichia coli isolates from
urine that were non-susceptible to amoxycillin–
clavulanate by the disk diffusion method. With
the NCCLS and CA-SFM methods, 74% and 13%,
respectively, of these isolates were susceptible to
amoxycillin–clavulanate. Therefore, the apparent
relatively poor efﬁcacy of amoxycillin–clavula-
nate against E. coli in French hospitals probably
reﬂects a methodological difference rather than a
localised resistance problem. This implies that
amoxycillin–clavulanate could be used as an
alternative to ﬂuoroquinolones for treatment of
E. coli urinary tract infections. Susceptibility tests
for amoxycillin–clavulanate should be standard-
ised worldwide.
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chia coli, MICs, NCCLS, susceptibility testing
Original Submission: 28 June 2004; Revised Submis-
sion: 8 October 2004; Accepted: 15 November 2004
Clin Microbiol Infect 2005; 11: 237–240
10.1111/j.1469-0691.2005.01075.x
Escherichia coli is the bacterial pathogen isolated
most frequently from clinical samples taken for
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diagnostic purposes in hospitals and in the
community [1–5]. This species is naturally sus-
ceptible to a large number of antibiotics, but the
emergence and spread of various resistance
mechanisms now limits the prescription of a
number of ﬁrst-line antibiotics. In the hospital
studied, the frequencies of amoxycillin and am-
oxycillin–clavulanate resistance within E. coli
have reached 45% and 40%, respectively (perso-
nal unpublished observations). However, the
distribution of isolates between non-susceptible
categories (i.e., ‘intermediate’ or ‘resistant’) varied
considerably for these two antimicrobial agents,
in that all the E. coli isolates that were non-
susceptible to amoxycillin were resistant, whereas
86.5% of the amoxycillin–clavulanate-non-sus-
ceptible isolates were classiﬁed as intermediate.
Meanwhile, the proportion of E. coli isolates
resistant to ﬂuoroquinolones increased from 5%
in 1999 to 12% at present, probably following an
increase in the consumption of this class of
antibiotics [5]. Fluoroquinolones are currently
the recommended empirical treatment for uncom-
plicated acute bacterial cystitis in women [6,7].
In exploring therapeutic alternatives to
ﬂuoroquinolones, the present study aimed to
characterise the resistance of E. coli to amoxycil-
lin–clavulanate. The combination of two active
agents in amoxycillin–clavulanate makes it more
difﬁcult to establish clinically relevant break-
points for in-vitro susceptibility tests [8]. Many
laboratories worldwide follow the NCCLS guide-
lines [9], but French laboratories follow the
recommendations of the Comite´ de l’Antibio-
gramme de la Socie´te´ Franc¸aise de Microbiologie
(CA-SFM, or Antibiogram Committee of the
French Society of Microbiology) [10]. The
CA-SFM and NCCLS guidelines differ in two
ways, namely the susceptibility breakpoints and
the concentration of clavulanate used. The objec-
tive of this study was to examine the effects of
these two sets of guidelines on the reported
susceptibility of urinary isolates of E. coli to
amoxycillin–clavulanate.
In November and December 2003, 100 non-
replicate consecutive E. coli isolates from urine
that were non-susceptible to amoxycillin–clavul-
anate according to the CA-SFM disk diffusion
method were collected. The susceptibility of each
isolate to amoxycillin–clavulanate (GlaxoSmith-
Kline, Evreux, France) was determined by the
agar dilution method according to NCCLS and
CA-SFM guidelines [9,10]. Both guidelines
recommend testing with a bacterial inoculum
of 104 CFU ⁄ spot. The differences for the
determination of the MIC of amoxycillin–clavul-
anate between the two sets of guidelines are listed
in Table 1. E. coli strain ATCC 25922 was included
in each test run as an internal control.
The amoxycillin–clavulanate MIC distributions
determined by the NCCLS and CA-SFM methods
were markedly different (Fig. 1), although the
MIC of amoxycillin–clavulanate for E. coli ATCC
25922 was 4 mg ⁄L by both methods. The MIC for
13 isolates classiﬁed as non-susceptible by the
routine disk diffusion test was 4 mg ⁄L; thus,
these isolates were susceptible by both agar
dilution methods. However, when the amoxycil-
lin concentration in the amoxycillin–clavulanate
combination was between 8 and 32 mg ⁄L, MICs
were lower with the NCCLS method, with a
further 60 isolates classed as susceptible by the
NCCLS method only. Only 12 isolates were
resistant to amoxycillin–clavulanate (MICs
Table 1. Differences between guidelines for the determin-
ation of MICs of amoxycillin–clavulanate by the agar
dilution method
Detail of method NCCLS CA-SFM
Clavulanate concentration 2:1 ratio of
amoxycillin : clavulanate
Fixed 2 mg ⁄L
MIC breakpoints (mg ⁄L)
Susceptible £ 8 ⁄ 4 £ 4 ⁄ 2
Intermediate 16 ⁄ 8 8 ⁄ 2-16 ⁄ 2
Resistant ‡ 32 ⁄ 16 > 16 ⁄ 2
Number of colonies for endpoint £ 1 £ 3
CA-SFM, Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie.
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Fig. 1. Distribution of amoxycillin–clavulanate MICs
determined by NCCLS (black bars) and Comite´ de l’An-
tibiogramme de la Socie´te´ Franc¸aise de Microbiologie
(grey bars) methods for 100 consecutive E. coli urinary
tract isolates that were non-susceptible to amoxycillin–
clavulanate by disk diffusion.
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‡ 32 mg ⁄L) by the NCCLS method, compared to
35 isolates (MIC > 16 mg ⁄L) by the CA-SFM
method.
The differences in the breakpoints (Table 1)
also had a marked effect on the amoxycillin–
clavulanate susceptibility categories. If the
NCCLS agar dilution method was taken as the
reference method, the CA-SFM disk diffusion
test gave the correct frequency of amoxycillin–
clavulanate resistance, but considerably overesti-
mated the frequency of intermediate isolates,
while the CA-SFM agar dilution method overes-
timated the frequencies of both intermediate
and resistant isolates. MICs were only measured
for isolates that were classiﬁed as non-suscept-
ible by the disk diffusion method, but by
extrapolating the results to all E. coli isolates, it
was estimated that 89.6% of isolates would be
fully susceptible to amoxycillin–clavulanate
according to NCCLS guidelines, compared to
64.4% according to CA-SFM guidelines. Simi-
larly, only 4.8% of isolates were resistant by
NCCLS criteria, compared to 14.4% by CA-SFM
criteria. These results demonstrated that the
large differences in the frequency of E. coli
isolates susceptible to amoxycillin–clavulanate
observed between France and other European
countries [8,11–13] are probably attributable
largely to technical differences in the guidelines
used for antimicrobial susceptibility testing and
in the MIC breakpoints used for the inter-
pretation of susceptibility. These susceptibility
differences reﬂect the amount of clavulanate
available to inhibit b-lactamase.
No clinical studies have assessed which sus-
ceptibility-testing method is the best predictor of
clinical efﬁcacy. However, the NCCLS break-
points were found to be fully predictive of
in-vivo efﬁcacy in a rat abscess model [14],
in which isolates that would be deﬁned as
intermediate to amoxycillin–clavulanate in vitro
according to CA-SFM methods were found to be
susceptible in vivo. In addition, a study in a
Yucatan miniature pig model showed that con-
centrations of amoxycillin–clavulanate similar to
those seen in human plasma had bactericidal
potential against E. coli strains [15]. The ob-
served discordance between the MIC value and
the efﬁcacy of the antimicrobial combination
was probably caused by an overestimation of
the MIC value generated by the ﬁxed concen-
tration of clavulanic acid. Given these results, it
is likely that all isolates intermediate by the
CA-SFM method are susceptible to amoxycillin–
clavulanate in vivo.
Considering the pharmacokinetic properties of
amoxycillin–clavulanate, this combination is
probably active against most urinary isolates of
E. coli [11]. In France, expert opinion is that
amoxycillin–clavulanate should not be used for
treatment of acute uncomplicated cystitis because
of the high rate of resistance in E. coli. This and
other studies [8,16] demonstrate that this asser-
tion is at least partially unfounded, even though
b-lactam agents tend to be less effective than non-
b-lactams in eradicating initial bacteriuria and in
preventing reoccurrence [7].
In conclusion, the apparent high frequency
of non-susceptibility of E. coli to amoxycillin–
clavulanate in French hospitals is probably
caused mostly by a methodological difference
rather than a localised resistance problem. Con-
sidering the worrying increase in the frequency of
ﬂuoroquinolone-resistant E. coli isolates, it seems
that amoxycillin–clavulanate could be used as an
alternative to ﬂuoroquinolones for the treatment
of E. coli infections, particularly urinary tract
infections. Susceptibility tests for amoxycillin–
clavulanate should be standardised worldwide
to avoid discrepancies resulting from technical
differences.
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ABSTRACT
This study assessed the age and gender distribu-
tion of Chlamydia trachomatis infections among
patients attending two clinics for sexually trans-
mitted diseases (STDs) in Slovenia. Between
January 1999 and December 2003, 1714 hetero-
sexual male and 892 heterosexual female patients
were tested for C. trachomatis. The prevalence of
C. trachomatis infection was 19.5% (n = 334) for
male patients and 10.7% (n = 96) for female
patients, with the highest prevalence in the group
aged 15–30 years. The prevalence decreased
between 2000 and 2003 among female patients.
The results support the implementation of routine
screening for C. trachomatis genital infection
among male and female patients aged < 30 years
attending STD clinics in Slovenia.
Keywords Chlamydia trachomatis, infection, preval-
ence, sexually transmitted disease, Slovenia, urethritis
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Chlamydia trachomatis has been recognised as a
major bacterial sexually transmitted disease (STD)
in north America and western Europe [1]. The
prevalence of infection for men in STD settings is
15–20%, with a corresponding ﬁgure for women
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